TABLE 1.
Clinical characteristics and levels of PPARGC1A methylation and mRNA of Parkinson’s disease patients and controls.
| PD | Control | P value | |
| Number | 90 | 81 | |
| Gender (male/female) | 43/47 | 39/42 | 1.000a |
| Age (years) | 64.83 ± 9.62 | 66.59 ± 9.46 | 0.231b |
| Age of onset (years) | 59.30 ± 11.51 | ||
| Disease duration (years) | 4.95 ± 4.08 | ||
| H&Y stage | 2.10 ± 0.99 | ||
| UPDRS III | 26.39 ± 17.23 | ||
| NMS | 7.07 ± 4.28 | ||
| HAMD | 6.91 ± 7.89 | ||
| HAMA | 7.77 ± 7.77 | ||
| MoCA | 22.62 ± 5.01 | ||
| LED | 408.70 ± 246.11 | ||
| Mean methylation level (%) | 7.18 ± 1.74 | 6.36 ± 1.28 | 0.007c |
| PPARGC1A expression level | 0.99 ± 1.61 | 2.85 ± 3.30 | 0.000c |
PD, Parkinson’s disease; H&Y stage, Hoehn and Yahr stage; UPDRS, Unified Parkinson’s Disease Rating Scale; NMS, Non-motor Symptoms Questionnaire; HAMD, Hamilton Rating Scale for Depression; HAMA, Hamilton Anxiety Scale; MoCA, Montreal Cognitive Assessment; LED, levodopa equivalent doses.aP-value for chi-square/Fischer’s exact test,bP-value for unpaired t-test, cP-value for Mann–Whitney U test.